Myriad Genetics, Inc. (MYGN) is currently trading at $4.17 with a Wall Street consensus price target of $3.37, which is 19.3% below the current price over the next 12 months. 9 analysts currently cover MYGN, with a consensus rating of Underperform - 11% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.0, while the most cautious has a target of $2.0.
MYGN operates in the Healthcare sector with a market capitalisation of $399M. The stock is down 32.1% year-to-date and is currently trading near the lower end of its 52-week range of $2.74 – $8.59.
Other Healthcare stocks with comparable size and valuation.
Upgrade/downgrade history for MYGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →